World News – CA – J&J Confirms Suspension of Covid-19 Vaccine Trial Due to Unexplained Illness

Jeff Sutherland & Riley Griffin | Bloomberg
Last updated on October 13, 2020 07:25 IST

Johnson & Johnson said his study of the Covid-19 vaccine was temporarily halted due to unexplained illness in a trial participant

Jake Sargent, a spokesperson for the New Brunswick, New Jersey company, confirmed an earlier report from health information provider STAT that the study was suspended from documentwrite («  »); googletagcmdpush (function () {googletagdefineOutOfPageSlot (‘/ 6516239 / outofpage_1x1_desktop’, ‘div-gpt-ad-1490771277198-0’) addService (googletagpubads ()); googletagpubadesRendering (agenable);

Earlier this month, Johnson & Johnson joined the shortlist of vaccine makers who have transferred an experimental coronavirus to advanced human studies in the US The company has since started dosing up to 60,000 volunteers, marking the first major trial of a Covid-19 inoculation that can work after a single injection

News of the shutdown comes after AstraZeneca Plc temporarily halted testing of its vaccine after a trial participant fell ill This study has resumed in a number of countries but remains on hiatus in the US

Business Standard has always strived to provide up-to-date information and commentary on developments that are of interest to you and which have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our determination and commitment to these ideals. Even in these difficult times stemming from Covid-19, we remain committed to keeping you informed and up to date with credible news, authoritative opinions and incisive commentary on relevant current issues.
However, we have a request

As we fight the economic impact of the pandemic, we need your support even more, so that we can continue to provide you with higher quality content Our subscription model has received an encouraging response from many of you, who have subscribed to our online content More subscribing to our online content can only help us achieve the goals of providing you with even better and more relevant content We believe in free, fair and credible Your support through more subscriptions can help us practice the journalism we are committed to

Support quality journalism and subscribe to Business Standard

Digital editor

Business Standard is pleased to inform you of the launch of « Business Standard Premium Services »

As a premium subscriber, you get unrestricted access on all devices to a range of services including:

Welcome to the premium Business Standard services offered to you free of charge by FIS
Please visit the Manage My Membership page to learn about the benefits of this program
Good reading!
Team Business Standard

Vaccine, Johnson & Johnson, coronavirus, vaccine trial